SNSE Faeth Therapeutics, Inc. Insider Trading

CFO-then Brian C Stephenson bought 13,634 shares in 6 transactions for $326,127.38 at FTH (recently listed).

Brian C Stephenson, who was CFO at the time, executed 6 separate purchases totaling 13,634 shares for $326,127.38 across three consecutive trading days (2026-06-29 to 2026-07-01), at prices ranging from $22.95 to $24.98 and a blended average of $23.92. This increased his holdings by 41.2% from 33,054 to 46,688 shares in a company that has traded publicly for only 11 days and carries a $31.8M market cap against a negative net income of $-170.2M. The concentrated buying activity in a newly listed unprofitable biotech firm, combined with the absence of a 52-week history to contextualize valuation, limits the interpretability of the signal; this filing merits examination for any planned equity structures or governance context that informed the timing and scale of accumulation.

Then-CFO Brian C Stephenson buys 15,641 shares for $401,268.52 across 8 transactions at Faeth Therapeutics (FTH), nearly doubling his stake to 33,054 shares.

Brian C Stephenson, who was CFO at the time, purchased 15,641 shares totaling $401,268.52 across 8 separate transactions on June 24-26, 2026, at prices ranging from $23.61 to $27.77, with a blended average price of $25.65. His holdings increased from 17,413 shares to 33,054 shares, a net increase of 89.8%. This substantial accumulation occurred while FTH was still a recent listing (8 trading days old) with a current price of $22.87, below the blended purchase average. The company reported a net income of $-170,236,000.00 and carries a market cap of $30,690,190.67, reflecting significant losses in its most recent fiscal year. The magnitude of the purchase relative to prior holdings, combined with the multi-day execution pattern and the company's unprofitable status, warrants examination of the circumstances and timing of this accumulation.

FTH CFO Brian C Stephenson buys 17,413 shares in 8 transactions for $405,920.62 post-IPO

Brian C Stephenson, who was CFO at the time, purchased 17,413 shares across 8 separate transactions on 2026-06-22 and 2026-06-23 for a combined $405,920.62, establishing an initial stake in Faeth Therapeutics following its recent listing 6 trading days prior. The purchases occurred at prices ranging from $20.23 to $25.91, with a blended average price of $23.31, and the current price stands at $24.54. This acquisition is noteworthy given the company's fundamental profile: Faeth reported net income of $-170,236,000.00 for its most recent full fiscal year, with a current market cap of $32,931,232.14, indicating the company is unprofitable. The pattern of multiple purchases at varying prices over two consecutive days during the early post-IPO phase warrants investor attention given the company's negative earnings backdrop.

Anand Kiran Parikh (then-CEO) purchases 2,806 shares of FTH at $19.76 on day 6 post-listing; holds 817,699 non-derivative shares; company unprofitable ($-170.2M net loss).

Anand Kiran Parikh, who was President and CEO at the time of filing, purchased 2,806 shares at $19.76 on 2026-06-22, six trading days after Faeth Therapeutics' listing. His non-derivative holdings increased to 817,699 shares post-transaction, with additional derivative holdings of 95,739 employee stock options remaining. The purchase occurred in a company with a net loss of $-170,236,000.00 and a market cap of $32,931,232.14. The current price of $24.54 as of 2026-06-24 reflects movement since the trade execution. Investors should note the insider's continued equity exposure through both non-derivative and option holdings in an unprofitable biotech entity during the early post-IPO period.

Millennium Management sells 17,076 shares for $538,114.34 while buying 4,215 shares for $141,364.00 at SNSE; net reduction of 12,861 shares.

Millennium Management, a 10% owner, executed 12 separate sales totaling 17,076 shares for $538,114.34 across April 2–7, 2026, while simultaneously making 5 purchases totaling 4,215 shares for $141,364.00. The net effect is a reduction of 12,861 shares, bringing holdings from 146,847 to 133,986 shares. Transaction prices ranged from $28.94 to $35.55, whereas the current stock price of $20.43 sits 44.4% below the 52-week high of $36.76, suggesting the insider sold into strength during early April. The company reports negative net income and a $27.4M market cap, indicating a loss-making biotech in a challenged position. The scale of net selling by a major shareholder warrants attention given the stock's recent 30-day decline of 30.1%.

Millennium Management LLC (10% owner) purchased 12.2K shares of SNSE across 10 transactions for $382.1K while selling 2.7K shares for $76.9K on Mar 31–Apr 1.

Millennium Management LLC executed a net purchase of 9,439 shares, increasing its stake from 138,292 to 147,731 shares across 10 buy transactions totaling 12.2K shares for $382.1K and 7 sale transactions totaling 2.7K shares for $76.9K between March 31 and April 1. The purchases occurred at prices ranging from $24.69 to $35.46, while the company trades at $20.43 (down 44.4% from its 52-week high of $36.76 and down 30.1% over 30 days). The filer is accumulating shares despite SNSE's negative net income of $-170.2M and market cap of $27.4M, alongside sharp recent price declines. The mixed buy-and-sell pattern across multiple price points suggests opportunistic execution rather than a simple conviction-driven accumulation, but the net effect is a material increase in a 10% holder's position in an unprofitable, volatile biotech stock.

Millennium Mgmt (10% Owner) makes 11 purchases & 6 sales at SNSE over 3 days, net buying 27,335 shares; post-trade holding: 145.7K shares

Millennium Management LLC filed a Form 4 at Sensei Biotherapeutics, Inc. (SNSE) covering 17 separate transactions across three trading days (2026-03-26 through 2026-03-30), comprising 11 purchases totaling 30,585 shares for $818,257.09 and 6 sales totaling 3,250 shares for $89,389.75, resulting in a net increase of 27,335 shares. The post-transaction holding of 145,678 shares represents a meaningful expansion from the pre-transaction level of 118,343 shares, as Millennium's position in SNSE has grown substantially. This activity occurs against a backdrop of notable price volatility: the current price of $20.43 sits -44.4% from the 52-week high of $36.76, while the 30-day change is -30.1%, meaning the transaction prices across all 17 legs were executed at levels well above the current market price. The company carries a net income of $-170,236,000.00 and a market cap of just $27,415,854.63, making Millennium's expanded stake particularly notable relative to the company's overall size.